EA201591522A1 - Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов - Google Patents

Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов

Info

Publication number
EA201591522A1
EA201591522A1 EA201591522A EA201591522A EA201591522A1 EA 201591522 A1 EA201591522 A1 EA 201591522A1 EA 201591522 A EA201591522 A EA 201591522A EA 201591522 A EA201591522 A EA 201591522A EA 201591522 A1 EA201591522 A1 EA 201591522A1
Authority
EA
Eurasian Patent Office
Prior art keywords
transplantate
owner
treatment
reactions against
exposed patient
Prior art date
Application number
EA201591522A
Other languages
English (en)
Other versions
EA030783B1 (ru
Inventor
Петер Гергели
Казухико Курияма
Original Assignee
Новартис Аг
Керин Фармасьютикал Ко.Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг, Керин Фармасьютикал Ко.Лтд. filed Critical Новартис Аг
Publication of EA201591522A1 publication Critical patent/EA201591522A1/ru
Publication of EA030783B1 publication Critical patent/EA030783B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01B—SOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
    • A01B1/00—Hand tools
    • A01B1/02—Spades; Shovels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Environmental Sciences (AREA)
  • Soil Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к способу лечения пациентов, которые подвергаются трансплантации гемопоэтических стволовых клеток (ТГСК) с применением мобилизованных стволовых клеток периферической крови при гемобластозах и у которых имеется значительный риск тяжелой острой реакции "трансплантат против хозяина" (GVHD).
EA201591522A 2013-02-20 2014-02-18 Способ лечения и/или предупреждения реакции "трансплантат против хозяина" у пациента, подвергаемого трансплантации гемопоэтических стволовых клеток EA030783B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361766830P 2013-02-20 2013-02-20
PCT/IB2014/059067 WO2014128611A1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Publications (2)

Publication Number Publication Date
EA201591522A1 true EA201591522A1 (ru) 2016-03-31
EA030783B1 EA030783B1 (ru) 2018-09-28

Family

ID=50236228

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591522A EA030783B1 (ru) 2013-02-20 2014-02-18 Способ лечения и/или предупреждения реакции "трансплантат против хозяина" у пациента, подвергаемого трансплантации гемопоэтических стволовых клеток

Country Status (22)

Country Link
US (2) US20160000811A1 (ru)
EP (1) EP2958624B1 (ru)
JP (2) JP6441822B2 (ru)
KR (1) KR102165514B1 (ru)
CN (1) CN105007981B (ru)
AU (1) AU2014220377B2 (ru)
BR (1) BR112015019197A2 (ru)
CA (1) CA2898565C (ru)
CY (1) CY1124191T1 (ru)
DK (1) DK2958624T3 (ru)
EA (1) EA030783B1 (ru)
ES (1) ES2873181T3 (ru)
HR (1) HRP20210891T1 (ru)
HU (1) HUE054330T2 (ru)
LT (1) LT2958624T (ru)
MX (1) MX369631B (ru)
PL (1) PL2958624T3 (ru)
PT (1) PT2958624T (ru)
RS (1) RS61933B1 (ru)
SI (1) SI2958624T1 (ru)
TW (1) TWI648050B (ru)
WO (1) WO2014128611A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015755C (en) * 2016-03-08 2024-01-30 Kyorin Pharmaceutical Co., Ltd. Treatment of hematopoietic stem cell transplant patients
WO2020022507A1 (ja) * 2018-07-27 2020-01-30 杏林製薬株式会社 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤
WO2022162409A1 (en) 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators
KR20230136603A (ko) 2021-01-28 2023-09-26 프리오테라 에스에이에스 S1p 수용체 조정제를 사용한 치료 방법
AU2023220748A1 (en) 2022-02-16 2024-07-25 Priothera Sas Methods of treatment with car cells in combination with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514193A (ja) * 1996-11-15 2002-05-14 バクスター、インターナショナル、インコーポレイテッド 同種幹細胞移植のためのコンディショニング
JPH11343242A (ja) * 1998-03-30 1999-12-14 Otsuka Pharmaceut Co Ltd 造血幹細胞移植用剤
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
JP4217620B2 (ja) * 2001-09-27 2009-02-04 杏林製薬株式会社 ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
MXPA05003080A (es) * 2002-09-19 2005-06-15 Kyorin Seiyaku Kk Derivado de amino alcohol, sales de los mismos y agentes inmunosupresores.
CN101014329B (zh) 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
JP4966019B2 (ja) * 2005-01-06 2012-07-04 キッセイ薬品工業株式会社 慢性移植片対宿主症におけるドライアイの予防および治療剤
EP2566954B2 (en) 2010-05-04 2022-11-02 Yeda Research and Development Co. Ltd. Immunotherapy using redirected allogeneic cells
BR112012028248A2 (pt) * 2010-05-06 2016-08-02 Novartis Ag derivados de sulfeto de diarila, seu uso, e kit

Also Published As

Publication number Publication date
EP2958624B1 (en) 2021-05-12
ES2873181T3 (es) 2021-11-03
CA2898565C (en) 2023-01-24
PT2958624T (pt) 2021-06-11
US11224604B2 (en) 2022-01-18
JP6441822B2 (ja) 2018-12-19
CN105007981B (zh) 2020-07-21
KR102165514B1 (ko) 2020-10-15
SI2958624T1 (sl) 2021-07-30
DK2958624T3 (da) 2021-06-07
JP6633170B2 (ja) 2020-01-22
AU2014220377A1 (en) 2015-08-06
HRP20210891T1 (hr) 2021-07-23
RS61933B1 (sr) 2021-07-30
MX369631B (es) 2019-11-14
BR112015019197A2 (pt) 2017-07-18
TW201511751A (zh) 2015-04-01
MX2015010833A (es) 2016-07-08
CN105007981A (zh) 2015-10-28
KR20150118149A (ko) 2015-10-21
EP2958624A1 (en) 2015-12-30
JP2019059748A (ja) 2019-04-18
JP2016509050A (ja) 2016-03-24
PL2958624T3 (pl) 2021-10-04
CA2898565A1 (en) 2014-08-28
AU2014220377B2 (en) 2017-05-04
TWI648050B (zh) 2019-01-21
CY1124191T1 (el) 2022-05-27
EA030783B1 (ru) 2018-09-28
US20160000811A1 (en) 2016-01-07
HUE054330T2 (hu) 2021-09-28
WO2014128611A1 (en) 2014-08-28
LT2958624T (lt) 2021-08-10
US20180153911A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
MX2021014748A (es) Kits, dispositivos descartables para reducir el oxigeno y metodos para usarlos.
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EA201590144A1 (ru) Rspo3-связывающие агенты и их применение
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
EA200971053A1 (ru) Способы лечения кожных язв
GT201600084A (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
EA201590088A1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
MX2015008190A (es) Tretaspanina 33 es una candidata para la terapia dirigida de anticuerpos para el tratamiento de linfomas de hodgkin de linfocitos b.
MX2021003798A (es) Terapia con celulas de placenta humana y celulas hematopoyeticas.
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2018011169A (es) Metodo para prevenir la enfermedad del injerto contra huesped.
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.
WO2012169897A8 (en) Weight reducing material
DE602004028876D1 (de) Verfahren zur verwendung regenerativer zellen bei der behandlung von nierenkrankheiten und störungen
UA113183C2 (xx) Спосіб лікування адикції

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment